Form 4: Tyra Biosciences COO Daniel Bensen Acquires 115,000 Stock Options

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, acquired 115,000 stock options on August 14, 2024, at an exercise price of $21.57.

Summary

• On August 14, 2024, Daniel Bensen, the Chief Operating Officer of Tyra Biosciences, acquired 115,000 stock options.
• The exercise price for these options is $21.57.
• The options vest monthly, with 1/48th of the shares vesting each month following August 14, 2024, contingent upon continuous service to Tyra Biosciences.
• The options expire on August 13, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, suggesting confidence in the company's future, but it's not overwhelmingly positive as it's a routine event.

Positives

• The acquisition of stock options by a key executive like the COO can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices in the sector.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule of 1/48th monthly is a standard vesting schedule.

Stakeholder Impact

• The stock option grant could potentially align the executive's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates